Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis

Medicine & Life Sciences

• 3-(1,3-benzodioxol-5-yl)-3-((((-1-((bis(2-thienylmethyl)amino)carbonyl)pentyl)amino)carbonyl)amino)propanoic acid 100%
• Integrin alpha4beta1 56%
• Autoimmune Experimental Encephalomyelitis 46%
• Demyelinating Diseases 16%
• Animals 16%
• Acute Disease 8%
• Myelin Sheath 8%
• Integrins 7%
• Multiple Sclerosis 7%
• Chronic Disease 5%
• Immunohistochemistry 5%
• Western Blotting 5%
• Therapeutics 5%
• Antigens 5%
• Cytokines 4%
• T-Lymphocytes 4%
• Inflammation 4%
• Antibodies 4%